Literature DB >> 22175869

Preliminary web-based measures development for GHB: expectancies, functions, and withdrawal.

L A R Stein1, Rebecca Lebeau, Mary Clair, Rosemarie Martin, Monte Bryant, Susan Storti.   

Abstract

BACKGROUND: Much of what is understood regarding gamma hydroxybutyrate (GHB) treatment is based on hospital case studies for overdose and withdrawal, and there are currently no measures developed specifically for GHB or its analogs (e.g., gamma butyrolactone and 1,4-butanediol) to assess drug effect expectancies, reasons for starting use, withdrawal effects, and knowledge and opinions about use.
OBJECTIVES: This pilot study (N = 61) was conducted to begin measures development to assess experiences, functions of use, and opinions regarding use as indicated by respondents taking a Web-based survey.
METHODS: Minimum average partial correlation and parallel analysis procedures are employed to create scales.
RESULTS: Scales were developed to assess expectancies, reasons for use, withdrawal, and knowledge/opinions of use with median α = .79 and that account for 8.69-24.17% of the variance.
CONCLUSION: Scales have relatively good psychometric properties and replication is needed. SCIENTIFIC SIGNIFICANCE: GHB-specific measures may greatly assist in furthering our understanding of protective and risk factors for use, and withdrawal phenomena.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22175869      PMCID: PMC4469129          DOI: 10.3109/00952990.2011.643970

Source DB:  PubMed          Journal:  Am J Drug Alcohol Abuse        ISSN: 0095-2990            Impact factor:   3.829


  33 in total

1.  Test-retest reliability of alcohol measures: is there a difference between internet-based assessment and traditional methods?

Authors:  Elizabeth T Miller; Dan J Neal; Lisa J Roberts; John S Baer; Sally O Cressler; Jane Metrik; G Alan Marlatt
Journal:  Psychol Addict Behav       Date:  2002-03

2.  Subtypes for classifying adolescents with marijuana use disorders: construct validity and clinical implications.

Authors:  Thomas F Babor; Charles Webb; Joseph A Burleson; Yifrah Kaminer
Journal:  Addiction       Date:  2002-12       Impact factor: 6.526

3.  Drugnet: A Pilot Study of Adult Recreational Drug Use via the WWW.

Authors:  Thomas Nicholson; John White; David Duncan
Journal:  Subst Abus       Date:  1998-09       Impact factor: 3.716

4.  Permanent neurologic damage from chronic gamma hydroxybutyrate abuse.

Authors:  Kelly S Barth; Steven Hines; Robert P Albanese
Journal:  Am J Addict       Date:  2006 Nov-Dec

5.  Adverse events, including death, associated with the use of 1,4-butanediol.

Authors:  D L Zvosec; S W Smith; J R McCutcheon; J Spillane; B J Hall; E A Peacock
Journal:  N Engl J Med       Date:  2001-01-11       Impact factor: 91.245

Review 6.  The involvement of gamma-hydroxybutyrate in reported sexual assaults: a systematic review.

Authors:  Zsófia Németh; Bernadette Kun; Zsolt Demetrovics
Journal:  J Psychopharmacol       Date:  2010-05-20       Impact factor: 4.153

7.  Gamma hydroxy butyrate use--New York and Texas, 1995-1996.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1997-04-04       Impact factor: 17.586

Review 8.  The effects and consequences of selected club drugs.

Authors:  Thomas E Freese; Karen Miotto; Cathy J Reback
Journal:  J Subst Abuse Treat       Date:  2002-09

9.  GHB use among Australians: characteristics, use patterns and associated harm.

Authors:  Louisa Degenhardt; Shane Darke; Paul Dillon
Journal:  Drug Alcohol Depend       Date:  2002-06-01       Impact factor: 4.492

10.  Gamma hydroxybutyrate: an ethnographic study of recreational use and abuse.

Authors:  Steven J Lee; Petros Levounis
Journal:  J Psychoactive Drugs       Date:  2008-09
View more
  1 in total

1.  Improving GHB withdrawal with baclofen: study protocol for a feasibility study for a randomised controlled trial.

Authors:  Anne Lingford-Hughes; Yash Patel; Owen Bowden-Jones; Mike J Crawford; Paul I Dargan; Fabiana Gordon; Steve Parrott; Tim Weaver; David M Wood
Journal:  Trials       Date:  2016-09-27       Impact factor: 2.279

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.